The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지

A case of Castleman's disease patient treated successfully with cyclic high-dose steroid therapy

주기적 고용량 부신피질 호르몬제 투여로 치료된 Castleman 병 1예

  • Cho, Sung-Won (Department of Internal Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine) ;
  • Chung, Hyoung-Jung (Department of Internal Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine) ;
  • Kim, Su-Hee (Department of Internal Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine) ;
  • Choi, Jong-Su (Department of Internal Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine) ;
  • Kang, Gil-Hyun (Department of Pathology, Gangneung Asan Hospital, University of Ulsan College of Medicine) ;
  • Oh, Ho-Suk (Department of Internal Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine)
  • 조성원 (울산대학교 의과대학 강릉아산병원 내과학교실) ;
  • 정형정 (울산대학교 의과대학 강릉아산병원 내과학교실) ;
  • 김수희 (울산대학교 의과대학 강릉아산병원 내과학교실) ;
  • 최종수 (울산대학교 의과대학 강릉아산병원 내과학교실) ;
  • 강길현 (울산대학교 의과대학 강릉아산병원 병리과학교실) ;
  • 오호석 (울산대학교 의과대학 강릉아산병원 내과학교실)
  • Received : 2008.02.27
  • Accepted : 2008.08.13
  • Published : 2010.07.01
⟨ Previous Next ⟩

Abstract

Castleman's disease is rare, and its cause is unknown. Although various treatments have been attempted, no standard treatment has been established for it. A 51-year-old male on hemodialysis with end-stage renal disease was admitted to our hospital with fever and myalgia. He was diagnosed with multicentric Castleman's disease (MCD) of the hyaline vascular type. Considering his underlying disease and general condition, cyclic high-dose steroid therapy (prednisolone 1 mg/kg/day for 5 days) was administered every 4 weeks, eight times in total. After this, no symptomatic manifestations of MCD or signs on computed tomography were observed. We report an immunocompromised patient diagnosed with MCD of the hyaline vascular type, who was successfully treated with cyclic high-dose steroid therapy.

Keywords

References

  1. Castleman B, Iverson L, Menendes VP. Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer 9:822-830, 1956 https://doi.org/10.1002/1097-0142(195607/08)9:4<822::AID-CNCR2820090430>3.0.CO;2-4
  2. Frizzera G. Castleman's disease and related disorders. Semin Diagn Pathol 5:346-364, 1988
  3. Bowne WB, Lewis JJ, Filippa DA, Niesvizky R, Brooks AD, Burt ME, Brennan MF. The management of unicentricand multicentric Castleman's disease: a report of 16 cases and a review of the literature. Cancer 85:706-717, 1999 https://doi.org/10.1002/(SICI)1097-0142(19990201)85:3<706::AID-CNCR21>3.0.CO;2-7
  4. Gaba AR, Stein RS, Sweet DL, Variakojis D. Multicentric giant lymph node hyperplasia. Am J Clin Pathol 69:86-90, 1978
  5. Frizzera G, Peterson BA, Bayrd ED, Goldman A. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicophathologic correlations in 15 patients. J Clin Oncol 3:1202-1216, 1985
  6. Chronowski GM, Ha CS, Wilder RB, Cabanillas F, Manning J, Cox JD. Treatmentof unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer 92:670-676, 2001 https://doi.org/10.1002/1097-0142(20010801)92:3<670::AID-CNCR1369>3.0.CO;2-Q
  7. Peterson BA, Frizzera G. Multicentric Castleman's disease. Semin Oncol 20:636-647, 1993
  8. Weisenburger DD, Nathwani BN, Winberg CD, Rappaport H. Multicentric angiofollicular lymph node hyperplasia: a clinicopathologic study of 16 cases. Hum Pathol 16:162-172, 1985 https://doi.org/10.1016/S0046-8177(85)80065-4
  9. Granddadam M, Dupin N, Calvez V, Gorin I, Blum L, Kernbaum S, Sicard D, Buisson Y, Agut H, Escande JP, Huraux JM. Exacerbations of clinical symptoms in human immunodeficiency virus type 1-infected patients with multicentric Castleman's disease are associated a high increase in Kaposi's sarcoma herpesvirus DNA load in peripheral blood mononuclear cells. J Infect Dis 175:1198-1201, 1997 https://doi.org/10.1086/593567
  10. Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Tacho L, Aozasa K, Nakahata T, Kawai H, Tagoh H, Komori T. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 74:1360-1367, 1989
  11. Casper C. The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br J Haematol 129:3-17, 2005 https://doi.org/10.1111/j.1365-2141.2004.05311.x
  12. Summerfield GP, Taylor W, Bellingham AJ, Goldsmith HJ. Hyaline-vascula varient of angiofollicular lymph node hyperplasia with systemic manifestations and response to corticosteroids. J Clin pathol 36:1005-1011, 1983 https://doi.org/10.1136/jcp.36.9.1005
  13. Herrada T, Cabanillas F, Rice L, Manning J, Pugh W. The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med 128:657-662, 1998 https://doi.org/10.7326/0003-4819-128-8-199804150-00010